Main Menu

The LES Deal of Distinction award recognizes major business transactions involving licensing, that exemplify best practices and creativity to achieve strategic product development objectives, with a significant impact on advancing innovation in the industry sectors that comprise LES which includes pharmaceutical and biomedical technology. This LES award specifically recognizes two deals that were negotiated by NIAID technology transfer officers with an array of partners in industry and academic institutions, or Industry University Government Interface (IUGI) sector.

Low cost rotavirus vaccine in developing countries, ROTASIIL, a heat stable rotavirus vaccine, was approved by the Drug General Controller of India in 2017. The Government of India subsequently ordered 3.8 million doses of ROTASIIL for its Universal Immunization Program. 

The NIH Technology Transfer Program has won the Licensing Executive Society’s Deals of Distinction award for 2022. The Deals of Distinction Award is given to an outstanding licensing deal from the past year. Steve Ferguson, Special Advisor at the NIH Office of Technology Transfer, recently attended the LES award ceremony to accept the award on NIH’s behalf. Continue reading to learn about this award-winning license agreement from Steve himself.

THE PROBLEM: Respiratory syncytial virus (RSV) is a common virus that typically causes mild, cold-like symptoms — but it can be deadly to older adults, young children and people with chronic heart or lung disease or weakened immune systems. Each year in the U.S., 60,000 to 160,000 adults 65 years and older are hospitalized, and up to 10,000 people die each year from RSV infection, according to the Centers for Disease Control and Prevention.
 

NIAID TTIPO’s extraordinary efforts in “COVID-19 Technologies Licensed Globally Through WHO Program” was recognized by the Licensing Executives Society (U.S.A. & Canada) in 2022 with a Deals of Distinction Award in the Industry-University-Government Interface Sector. This award acknowledged the collaborative efforts put forth by the WHO, Medicines Patent Pool (MPP) and the NIH for COVID-19 technologies licensed globally through the WHO program.

The United States Patent and Trademark Office (USPTO) recognized NIAID TTIPO’s public health-centered patent management efforts with the Patents for Humanity: COVID-19 category award with the USPTO announcing the award on December 15, 2022. NIAID, Scripps Research Institute, and Dartmouth College invented stabilized coronavirus spike proteins, which were essential to the development of the COVID-19 vaccines used today. The vaccines that incorporate these stabilized spike proteins have been instrumental in combating the COVID-19 pandemic.

Rotavirus is a disease that affects nearly every child worldwide. While most cases have mild symptoms, it is responsible for one third of infant hospitalizations for severe diarrhea and kills an estimated 200,000 children a year, mostly in developing countries. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) developed vaccine formulations to address the six most common forms of rotavirus.

Rotavirus is a disease that affects nearly every child worldwide. While most cases have mild symptoms, it is responsible for one third of infant hospitalizations for severe diarrhea and kills an estimated 200,000 children a year, mostly in developing countries. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) developed vaccine formulations to address the six most common forms of rotavirus.

Human papilloma virus (HPV) is the most common sexually transmitted infection in the United States. The Centers for Disease Control and Prevention estimates that about 6.2 million Americans are infected with genital HPV each year and that over half of all sexually active men and women become infected at some time in their lives. While most HPV infections are cleared by the body’s own defense system and do not lead to cancer, virtually all cases of cervical cancer are linked to HPV infection.

BIO 2007 Innovation Corridor “Best Poster” Award

The poster presented by Anna Z. Amar, Technology Development Associate, National Institute of Allergy and Infectious Diseases (NIAID), NIH – for a Novel Protein for Development of a Chlamydial Vaccine – was awarded “Best Poster” at the BIO 2007 Convention.